"From Research to Industry"

A fireside chat with biotech ecosystem key players to ignite the scaling up process of invention and bio-entrepreneurial skills

Day 1 

“Academic Breakthroughs to Industrial Applications: Pioneering Biotechnological Product Development”

Sara is a Partner and Patent Attorney at Potter Clarkson with an academic background in microbial molecular biology.  She specialises in advising and working with biotech start-ups, primarily in the industrial biotechnology and synthetic biology space.  She is deeply involved in the ecosystem, sitting on a number of committees in these areas, including the Industrial Biotechnology Leadership Forum and the Bioindustry Association’s Engineering Biology Advisory Committee in the UK, and alongside Liz Fletcher at the Industrial Biotechnology Innovation  Centre and Fiona Mischel at SynBioBeta, co-founded the Women in Synthetic Biology network.


Dr Emma Ball is a biotechnology commercialization expert with over 20 years’ experience.  Her current role is Head of Ecosystem Development across Asia Pacific, Middle East, Africa (AMEA) at global genomics leader, Illumina (NASQAQ: ILMN).  The role involves strategic partnering with startups, corporates, governments and academia to catalyze innovation in genomics across the region.  Prior to joining Illumina in 2021, Emma was at biotherapeutics and vaccines company, CSL Limited (ASX: CSL) for 15 years, most recently as Global Head of Search & Evaluation and Director Strategy & BD.  Prior to joining CSL, Emma worked in project management in small biotech, both ASX-listed and private. She holds a PhD from the University of Melbourne, having trained initially as a molecular biologist, and a number of business qualifications including an MBA.


Husna Nugrahapraja is the Head of Integrated Laboratory and NGS at Bandung Institute of Technology. He completed his doctoral program from Scuola Superiore Sant’Anna Pisa, Italy, in 2015. Currently, his research focused on data analysis molecular data derived from Next-Generation Sequencing (NGS), Genomics and Transcriptomics, and Identification and Characterization of Non-Coding RNA (miRNA, lncRNA, circRNA, etc.). 



“Connecting The Dots: Integrating Bio-based Technology Into the Future of Industry”

Alfred works at SynBioBeta, focusing on connecting SynBio leaders in industry, academia, tech & finance. He is also Co-founder of DeSci London and a PhD candidate at Imperial College London, his research focuses on the intersection of SynBio and AI. He is passionate about moving the bioeconomy forward by enhancing communication and collaboration.


David Soukhasing serves as the Managing Director of ANGIN, Indonesia's largest network of prominent angel investors. Under his leadership, ANGIN has guided a group of 62 angel investors and facilitated investments in over 33 Indonesian entrepreneurs in the past three years. He boasts a distinguished academic background with two Master's Degrees: one in Innovation and Entrepreneurship from HEC Paris and another in Corporate Law and Finance from Sciences Po, France. Beyond his role at ANGIN, David contributes his expertise as an Advisor at Meridia and as a Venture Partner at both Teja Ventures and Spiral Ventures. 


Arni Yusnita is the Head of Pharmaceuticals, Cosmetics, and Traditional Medicine working group under Indonesian Ministry of Industry. She has been involved in the government effort to build pharmaceutical industry in Indonesia. Pharmaceuticals, cosmetics, and medical devices industry is listed as one of the top priority industries in Indonesian Government Regulation number 14 of 2015 on National Industrial Development Master Plan 2015-2035. The priority industries will be the main drivers of Indonesia’s economy. 

Day 3

“Navigating the SynBio and Biotech Startup and Company Landscape: Insights from Industry Leaders”

Dr. Novalia Pishesha, the co-founder and CEO of Cerberus Therapeutics, established the company in 2022. Located in Cambridge, Massachusetts, USA, Cerberus Therapeutics specializes in developing nanobody technology with a focus on autoimmunity and infectious diseases. Dr. Pishesha completed her PhD in Biological Engineering at the Massachusetts Institute of Technology (MIT) in the USA, followed by postdoctoral fellowships at both MIT and Harvard University


Jake Wintermute is a Developer Evangelist at Ginkgo Bioworks, a company headquartered in Boston USA, known for its pioneering work in synthetic biology. Ginkgo Bioworks specializes in programming cells for a variety of applications, ranging from food production to material synthesis and therapeutic development. Their services span from enzymatic processes to biosecurity solutions. Jake earned his PhD in systems biology from Harvard University. Prior to joining Ginkgo, he was a group leader at the CRI in Paris, France, which focused on drug discovery for neglected diseases, citizen science and synthetic biology education. 


Andreas Donny is the Head of Corporate Relationship at PT Etana Biotechnologies Indonesia, one of the biopharmaceutical industries in Indonesia. Prior to joining Etana, he served as the Deputy Director of Biologic Product Production Facility Control at Badan Pengawasan Obat dan Makanan. He earned a Master's degree in Medical Biotechnology from Wageningen University. His interest in investment and business development of biologic products in Indonesia is a driving force behind his role in shaping and fostering corporate relationships at PT Etana Biotechnologies Indonesia.